You may not realize you’ve benefited from HIV research. But if you’ve received a treatment that was approved through a recent ...

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...

Stuart and Molly Sloan add to their 2022 transformational gift to boost their impact on research and care SEATTLE – July 22, 2025 – A Fred Hutch Cancer Center outpatient complex serving more than ...

Our research on cell-based therapies also includes cutting-edge immunotherapies that harness the patient’s own immune cells to fight disease, including genetic engineering of immune cells to attack ...

HICOR’s Value in Cancer Care Initiative (VCCI) engages oncology providers, patient partners, payers, health system representatives and researchers to improve the value of cancer care delivery in ...

Affiliate Professor, Herbold Computational Biology Program, Public Health Sciences Division, Fred Hutch Affiliate Professor, Herbold Computational Biology Program Public Health Sciences Division, Fred ...

A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...

We’ve all seen the back and forth in the news about diet studies, even within the last few months. After a week or two, the hubbub died down, only to be replaced by a slew of fresh headlines touting a ...

Bisphosphonates are popular bone-targeting drugs. Older people take them to prevent and treat osteoporosis. Breast cancer patients, particularly those with metastatic disease, take them to prevent and ...

After being diagnosed and treated for breast cancer three separate times, Liza Bernstein, 51, of Los Angeles has her life, her family and friends, her hopes and dreams, her art, and a renewed sense of ...

The good news? Enrollment in new cancer therapy clinical trials has returned to normal, at least within one large trial network, a year after the pandemic began. The bad news? Normal trial enrollment ...